<\/p>\n
Admenta<\/strong> er en oral tablett fra Sun Pharma som inneholder memantine 5 mg<\/strong> \u2014 en uncompetitive NMDA receptor antagonist<\/strong> used for the symptomatic treatment of moderate-to-severe Alzheimer's disease<\/strong>. Memantine is ikke<\/strong> indicated for mild Alzheimer's. Slow upward titration over 4 weeks: 5 mg week 1, 10 mg week 2 (5 mg twice daily), 15 mg week 3, 20 mg week 4 onwards (10 mg twice daily)<\/strong>. Generally well tolerated — main side effects are dizziness, headache, constipation and confusion. Reduce dose if eGFR < 30 mL\/min<\/strong>. Often combined with donepezil in moderate-to-severe disease for additive cognitive benefit.<\/p>\n<\/div>\n \ud83d\udce6 Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis pakken din ikke ankommer innen 20 virkedager, sender vi ny.<\/p>\n V\u00e5re generiske legemidler kommer fra WHO-GMP-sertifiserte produsenter og sendes over hele verden i diskret, n\u00f8ytral emballasje \u2014 ingen legemiddelnavn p\u00e5 utsiden av pakken. Kortbetalinger h\u00e5ndteres av en regulert betalingsbehandler (kontoutskrifter viser en regulert kortbetalingsprosessor \u2014 aldri \u201cMedsBase\u201d eller noe legemiddelnavn). Krypto og SEPA bankoverf\u00f8rsel godtas ogs\u00e5. Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy.<\/p>\n Admenta is an oral tablet from Sun Pharma containing memantine hydrochloride 5 mg<\/strong>. Memantine is a low-affinity, voltage-dependent, uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) glutamate receptor<\/strong>. It is mechanistically distinct from the cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and works through the second major pathway implicated in Alzheimer's disease — glutamate excitotoxicity.<\/p>\n Admenta from Sun Pharma is a 5 mg memantine tablet — the strength used during the mandatory 4-week up-titration to the 20 mg\/day maintenance dose. Maintenance dosing is two 5 mg tablets twice daily (4 tablets total per day). Memantine is licensed only for moderate-to-severe Alzheimer's disease<\/strong> — not mild. It is the standard add-on to a cholinesterase inhibitor (typically donepezil) when patients progress past the mild stage, and produces additive cognitive and functional benefit with minimal increase in side effects.<\/p>\n Alzheimer's disease causes chronic excessive glutamate signalling at NMDA receptors — a process called glutamate excitotoxicity<\/strong>. Constant low-level NMDA activation damages neurons and disrupts the signal-to-noise ratio that the brain needs for learning and memory. Memantine addresses this through a unique mechanism:<\/p>\n Start p\u00e5 kognitiv nytte: synlig ved 4\u201312 uker<\/strong> after reaching the maintenance 20 mg\/day dose; peak benefit at 6 months.<\/p>\n Admenta is ikke<\/strong> indikert for: mild Alzheimer's disease<\/strong> (cholinesterase inhibitors are first-line at this stage), mild cognitive impairment without dementia, frontotemporal dementia, or as a cognitive enhancer in healthy adults.<\/p>\n Admenta comes at 5 mg<\/strong> tablets. The titration schedule is mandatory — jumping straight to 20 mg\/day causes intolerable confusion and dizziness in most patients.<\/p>\n Standard 4-week titration:<\/strong><\/p>\n Common (worst during titration, settle once on maintenance):<\/strong><\/p>\n Mindre vanlige:<\/strong><\/p>\n Rare but seek medical review:<\/strong><\/p>\nHvorfor bestille fra MedsBase<\/h3>\n
What Is Admenta?<\/h2>\n
How Does Admenta Work?<\/h2>\n
\n
Bruk og indikasjoner<\/h2>\n
\n
Admenta Dosage and How to Take — SLOW TITRATION<\/h2>\n
\n
How to Take Admenta Properly<\/h3>\n
\n
Side Effects of Admenta<\/h2>\n
\n
\n
\n
Advarsler og forholdsregler<\/h2>\n
\n
Contraindications — Who Should NOT Take Admenta<\/h2>\n
\n
Legemiddelinteraksjoner<\/h2>\n